Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review.

Barrett McCormick, Matthew A Meissner, Jose A Karam, Christopher G Wood
{"title":"Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review.","authors":"Barrett McCormick,&nbsp;Matthew A Meissner,&nbsp;Jose A Karam,&nbsp;Christopher G Wood","doi":"10.3233/KCA-170016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Locally advanced and metastatic renal cell carcinoma (RCC) is associated with poor survival outcomes. The integration of presurgical systemic therapy with targeted molecular agents prior to surgical resection of RCC tumors has been utilized to improve on these outcomes. These agents may be associated with an increased risk of perioperative complications due to their action on angiogenesis and cell proliferation.</p><p><strong>Objective: </strong>To examine the evidence for the incidence and severity of perioperative complications following presurgical targeted therapy for locally advanced or metastatic RCC.</p><p><strong>Methods: </strong>We performed a systematic review of retrospective studies, prospective clinical trials, and meta-analyses using key search terms in PubMed and Medline. Studies were screened for eligibility and data were extracted by the authors. A qualitative analysis was performed and the complications for available targeted agents was reported.</p><p><strong>Results: </strong>Retrospective analyses and small prospective trials indicate varying complication rates and types based on presurgical therapies. While some studies indicate a possible increase in wound-related complications, other studies did not show similar results. Additional unique complications reported include an increase in surgical adhesions. There was not any significant difference in overall or bleeding complications.</p><p><strong>Conclusions: </strong>Overall, these studies demonstrate an acceptable level of surgical complications that should not discourage the clinician considering presurgical therapy. The results of pending trials looking at presurgical therapies will provide further information.</p>","PeriodicalId":74039,"journal":{"name":"Kidney cancer (Clifton, Va.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/KCA-170016","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney cancer (Clifton, Va.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/KCA-170016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Background: Locally advanced and metastatic renal cell carcinoma (RCC) is associated with poor survival outcomes. The integration of presurgical systemic therapy with targeted molecular agents prior to surgical resection of RCC tumors has been utilized to improve on these outcomes. These agents may be associated with an increased risk of perioperative complications due to their action on angiogenesis and cell proliferation.

Objective: To examine the evidence for the incidence and severity of perioperative complications following presurgical targeted therapy for locally advanced or metastatic RCC.

Methods: We performed a systematic review of retrospective studies, prospective clinical trials, and meta-analyses using key search terms in PubMed and Medline. Studies were screened for eligibility and data were extracted by the authors. A qualitative analysis was performed and the complications for available targeted agents was reported.

Results: Retrospective analyses and small prospective trials indicate varying complication rates and types based on presurgical therapies. While some studies indicate a possible increase in wound-related complications, other studies did not show similar results. Additional unique complications reported include an increase in surgical adhesions. There was not any significant difference in overall or bleeding complications.

Conclusions: Overall, these studies demonstrate an acceptable level of surgical complications that should not discourage the clinician considering presurgical therapy. The results of pending trials looking at presurgical therapies will provide further information.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾细胞癌术前全身治疗的手术并发症:系统回顾。
背景:局部晚期和转移性肾细胞癌(RCC)与较差的生存结果相关。RCC肿瘤手术切除前的术前全身治疗与靶向分子药物的整合已被用于改善这些结果。由于这些药物对血管生成和细胞增殖的作用,它们可能与围手术期并发症的风险增加有关。目的:探讨局部晚期或转移性肾细胞癌术前靶向治疗围手术期并发症的发生率和严重程度。方法:我们使用PubMed和Medline的关键搜索词对回顾性研究、前瞻性临床试验和荟萃分析进行了系统综述。对研究的合格性进行筛选,并由作者提取数据。进行了定性分析,并报告了可用靶向药物的并发症。结果:回顾性分析和小型前瞻性试验表明,基于术前治疗的并发症发生率和类型不同。虽然一些研究表明可能会增加与伤口相关的并发症,但其他研究没有显示出类似的结果。其他独特的并发症包括手术粘连的增加。总体或出血并发症无显著差异。结论:总的来说,这些研究表明手术并发症的可接受水平不应阻碍临床医生考虑术前治疗。正在进行的手术前治疗试验的结果将提供进一步的信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review. Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1